Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care
Although Tal QW and Q2W are associated with higher total per-patient costs compared with usual care, they offer improved clinical effectiveness, resulting in lower cost per responder. These findings suggest greater economic value for Tal in the treatment of TCE RRMM.
Authors
- TIANZE JIAO
- Hans Chulhee Lee
- J Wang
- Chelsey Yang (ORCID: https://orcid.org/0000-0003-4777-2334)
- Ariel Felipe Grajales-Cruz (ORCID: https://orcid.org/0000-0003-0999-1771)
- Xinke Zhang (ORCID: https://orcid.org/0000-0002-3527-2140)
- Joseph A. Goble
- Fan Mu
- Neel Patel
- Yi-Hsuan Liu
Institutions
- NHS Blood and Transplant (GB)
- Johnson & Johnson (United States) (US)
- Sarah Cannon Research Institute (GB)
- University of Florida (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-01-03
- DOI
- https://doi.org/10.1080/13696998.2025.2604457
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00